

PemuPur™ START Polymer Toxicology Studies

INGREDIENTS: Microcrystalline cellulose (and) Sphingomonas ferment extract (and) Cellulose gum

The toxicology studies summarized below were performed on materials with chemical compositions representative of PemuPur™ START Polymer. Therefore, this toxicology data is expected to be predictive of the toxicity of the commercial grades of PemuPur™ START Polymer.

<u>INGREDIENT</u>	<u>TOXICOLOGY RESULTS</u>	<u>CONCLUSION</u>
Microcrystalline cellulose	See CIR ¹ report: Final Report March 23, 2009	Safe as used
Cellulose gum	See CIR ¹ reports: Final Report March 23, 2009 JACT 5(3):1-59, 1986	Safe as used

¹CIR reports are available at www.cir-safety.org

SPHINGOMONAS FERMENT EXTRACT: The remainder of this document reflect data on the Sphingomonas ferment extract of this product. The toxicology studies summarized below were performed on materials with chemical compositions representative of Sphingomonas ferment extract. Tests conducted prior to 2005.

<u>TEST</u>	<u>RESULTS</u>	<u>CONCLUSION</u>
Acute oral toxicity	A feeding study of test material up to 5000 mg/kg resulted in no deaths.	Oral LD50 >5000 mg/kg (rat)
Acute Inhalation	A 4-hour exposure of test material at nominal concentration resulted in no deaths.	LC50 >5 mg/l 4-hour (rat)

Lubrizol Advanced Materials, Inc. / 9911 Brecksville Road, Cleveland, Ohio 44141-3247 / TEL: 800.379.5389 or 216.447.5000

Lubrizol Advanced Materials, Inc. ("Lubrizol") hopes that you have found the information provided helpful, but you are cautioned that this material, including any prototype formulas, is for informational purposes only and you are solely responsible for making your own assessment of appropriate use of the information. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAWS, LUBRIZOL MAKES NO REPRESENTATIONS, GUARANTEES, OR WARRANTIES (WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE), INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR REGARDING THE COMPLETENESS, ACCURACY, OR TIMELINESS OF ANY INFORMATION. Lubrizol does not guarantee how the materials referenced herein will perform in combination with other substances, in any methods, conditions, or processes, with any equipment, or in non-laboratory environments. BEFORE COMMERCIALIZATION OF ANY PRODUCT CONTAINING THESE MATERIALS, YOU SHOULD THOROUGHLY TEST SUCH PRODUCT, INCLUDING HOW THE PRODUCT IS PACKAGED, TO DETERMINE ITS PERFORMANCE, EFFICACY, AND SAFETY. You are solely responsible for the performance, efficacy, and safety of any products you manufacture.

Lubrizol shall not be liable, and you shall assume all risk and responsibility for, any use or handling of any material. Any claims may not be approved in all jurisdictions. Any entity making claims related to these products is responsible for complying with local laws and regulations. Nothing contained herein is to be considered as permission, recommendation, or inducement to practice any patented invention without permission of the patent owner, and it is your sole responsibility to determine if any issues related to patent infringement of any component or combination of components relating to the information provided exists. You acknowledge and agree that you are using the information provided herein at your own risk. If you are dissatisfied with the information provided by Lubrizol, your exclusive remedy shall be to not use the information.

For further information, please visit: www.lubrizol.com/Beauty

TEST

Chronic Oral Toxicity

RESULTS

Repeated oral administration of the test material to rats by gavage for a period of twenty-eight consecutive days at dose levels of up to 1000 mg/kg/day did not result in any toxicologically significant changes in the parameters measured.

CONCLUSION

No adverse effects observed in long-term feeding studies with rats (NOEL) was 1,000 mg/kg/day. (OECD 407)

Eye Irritation

Single ocular administration with observation period at 24-, 48- and 72-hours post-treatment. Only transient and minor reaction to treatment.

Non-Irritating to eye (rabbit) (OECD 405)

Skin irritation

Topical applications (guinea pig) of test material at 50% concentration in arachis oil with an occluded dressing for 24hr did not result in irritation.

Non-irritating (guinea pig)

Skin sensitization

Skin sensitization testing (OECD 406) was conducted. The test material produced a 0% (0/10) sensitization rate at 25% concentration of test material in arachis oil. This was the maximum tested concentration.

Non-sensitizing (guinea pig) (OECD 406)

Chromosomal Aberrations

Chromosome Aberration Test (*in vitro*) in Human Lymphocytes mammalian cells with the test material did not induce any statistically significant increases in the frequency of cells with aberrations as compared to control materials.

Non-clastogenic. (OECD 473)

Mutagenicity

Reverse Mutation Assay "AMES TEST" of the test material using Salmonella typhimurium and Escherichia coli, was tested up to the maximum recommended dose level of 5000 µg/plate. No significant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test material, either with or without metabolic activation.

Non-mutagenic. (OECD 471)